David Hardisson

10.0k citations

158 papers · 7.0k indexed · 2 hit papers · h-index 42

Impact in

Cancer Research top 0.5%
- Breast Cancer Treatment Studies
Oncology top 1%
- Cancer Cells and Metastasis
- Cancer-related Molecular Pathways

Papers in ⓘ

Oncology 53
- Cancer Cells and Metastasis 13
- HER2/EGFR in Cancer Research 11
Molecular Biology 51

Co-authors: David Sarrió (14 shared papers)Gema Moreno‐Bueno (18 shared papers)Socorro Marıá Rodríguez-Pinilla (7 shared papers)José Palacios (24 shared papers)Marta Mendiola (45 shared papers)Amparo Cano (4 shared papers)José Palacios (1 shared paper)Francisco Calero Calero (6 shared papers)
Journals: Modern Pathology (6 papers)Journal of Clinical Oncology (4 papers)Clinical & Translational Oncology (4 papers)Histopathology (4 papers)The Journal of Pathology (4 papers)
Partner nations: Spain United States United Kingdom

In The Last Decade

David Hardisson

148 papers receiving 6.9k citations

Hit Papers

align trajectories log scale

Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation 2012 · 783 citations

Peers

Countries citing papers authored by David Hardisson

Since Specialization

Citations

This map shows the geographic impact of David Hardisson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Hardisson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Hardisson more than expected).

Fields of papers citing papers by David Hardisson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Hardisson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Hardisson. The network helps show where David Hardisson may publish in the future.

Co-authors

The 25 scholars most cited alongside David Hardisson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Hardisson Line = papers co-authored together David Hardisson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 158 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype Cancer Research ·David Sarrió, Socorro Marıá Rodríguez-Pinilla, David Hardisson, Amparo Cano, Gema Moreno‐Bueno, José Palacios Hit paper breakdown →	2008	842
2	Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation BMC Biology ·Maria Vinci, Sharon Gowan, Frances Boxall, Lisa Patterson, Miriam Zimmermann, William Court, C. Lomas, Marta Mendiola, David Hardisson, Suzanne A. Eccles Hit paper breakdown →	2012	783
3	Prognostic Significance of Basal-Like Phenotype and Fascin Expression in Node-Negative Invasive Breast Carcinomas Clinical Cancer Research ·Socorro Marıá Rodríguez-Pinilla, David Sarrió, Emiliano Honrado, David Hardisson, Francisco Calero Calero, Javier Benı́tez, José Palacios	2006	277
4	FGFR1 Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas Clinical Cancer Research ·Jorge S. Reis‐Filho, Peter T. Simpson, Nicholas C. Turner, Maryou Ballo Lambros, Chris Jones, Alan Mackay, Anita Grigoriadis, David Sarrió, Kay Savage, Tim Dexter, Marjan Iravani, Kerry Fenwick, Barbara L. Weber, David Hardisson, Fernando Schmitt, José Palacios, Sunil R. Lakhani, Alan Ashworth	2006	215
5	Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer Modern Pathology ·Socorro Marıá Rodríguez-Pinilla, David Sarrió, Gema Moreno‐Bueno, Yolanda Rodriguez-Gil, Miguel Ángel Martínez Martínez, Lucía Hernández, David Hardisson, Jorge S. Reis‐Filho, José Palacios	2007	199
6	Abnormalities of the APC/β-catenin pathway in endometrial cancer Oncogene ·Gema Moreno‐Bueno, David Hardisson, Carolina Sánchez, David Sarrió, Raúl Cassia, Ginesa García‐Rostán, Jaime Prat, Mingzhou Guo, James G. Herman, Xavier Matías‐Guiu, Manel Esteller, José Palacios	2002	195
7	Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: Relationships with abnormal E‐cadherin and catenin expression and microsatellite instability International Journal of Cancer ·David Sarrió, Gema Moreno‐Bueno, David Hardisson, Carolina Sánchez‐Estévez, Mingzhou Guo, James G. Herman, Carlos Gamallo, Manel Esteller, José Palacios	2003	170
8	The miR-200 family controls -tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients Endocrine Related Cancer ·Susanna Leskelä, Luis J. Leandro‐García, Marta Mendiola, Jorge Barriuso, Lucía Inglada‐Pérez, Inés G. Muñoz, Beatriz Martı́nez-Delgado, Andrés Redondo, J. de Santiago, Mercedes Robledo, David Hardisson, Cristina Rodríguez‐Antona	2010	168
9	Lysyl Oxidase–Like 2 as a New Poor Prognosis Marker of Squamous Cell Carcinomas Cancer Research ·Héctor Peinado, Gema Moreno‐Bueno, David Hardisson, Eduardo Pérez-Gómez, Vanesa Santos, Marta Mendiola, Juan Ignacio de Diego, Manuel Nistal, Miguel Quintanilla, Francisco Portillo, Amparo Cano	2008	167
10	Molecular pathogenesis of head and neck squamous cell carcinoma European Archives of Oto-Rhino-Laryngology ·David Hardisson	2003	153
11	Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions Oncogene ·David Sarrió, Belén Perez‐Mies, David Hardisson, Gema Moreno‐Bueno, Asunción Suárez, Amparo Cano, Jorge Martı́n-Pérez, Carlos Gamallo, José Palacios	2004	152
12	Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis Carcinogenesis ·Antonio Isidoro, E. Casado, Andrés Redondo, Paloma Acebo, Enrique Espinosa, Andrés M. Alonso, Paloma Cejas, David Hardisson, Juan Ángel Fresno Vara, Cristóbal Belda-Iniesta, Manuel González-Barón, José M. Cuezva	2005	138
13	Lysyl oxidase‐like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal‐like breast carcinomas EMBO Molecular Medicine ·Gema Moreno‐Bueno, Fernando Salvador, Alberto Martín, Alfredo Floristán, Eva P. Cuevas, Vanesa Santos, Amalia Montes, Saleta Morales, María Ángeles Castilla, Alejandro Rojo‐Sebastián, Alejandra Martínez, David Hardisson, Katalin Csiszár, Francisco Portillo, Héctor Peinado, José Palacios, Amparo Cano	2011	136
14	Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. PubMed ·Gema Moreno‐Bueno, Carolina Sánchez‐Estévez, Raúl Cassia, Sandra Rodríguez, Ramón Díaz‐Uriarte, Orlando Domı́nguez, David Hardisson, Miguel Andújar, Jaime Prat, Xavier Matías‐Guiu, Juan C. Cigudosa, José Palacios	2003	118
15	Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas The Journal of Pathology ·Peter T. Simpson, JS Reis‐Filho, MBK Lambros, Chris Jones, D Steele, Alan Mackay, Marjan Iravani, Kerry Fenwick, Tim Dexter, Ann-Britt Jones, Lynne Reid, Leonard Da Silva, SJ Shin, David Hardisson, Alan Ashworth, Schmitt Fc, José Palacios, Sunil R. Lakhani	2008	113
16	Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer Breast Cancer Research and Treatment ·Socorro Marıá Rodríguez-Pinilla, Emiliano Honrado, David Hardisson, Javier Benı́tez, José Palacios	2006	111
17	Abnormalities of E‐ and P‐cadherin and catenin (β‐, γ‐catenin, and p120^ctn) expression in endometrial cancer and endometrial atypical hyperplasia The Journal of Pathology ·Gema Moreno‐Bueno, David Hardisson, David Sarrió, Carolina Sánchez, Raúl Cassia, Jaime Prat, James G. Herman, Manel Esteller, Xavier Matías‐Guiu, José Palacios	2003	111
18	The PTEN/NRF2 Axis Promotes Human Carcinogenesis Antioxidants and Redox Signaling ·Ana I. Rojo, Patricia Rada, Marta Mendiola, Ana Ortega-Molina, Katarzyna Wojdyła, Adelina Rogowska-Wrzesińska, David Hardisson, Manuel Serrano, Antonio Cuadrado	2014	109
19	Cyclin D1 gene (CCND1) mutations in endometrial cancer Oncogene ·Gema Moreno‐Bueno, Sandra Rodríguez, Carolina Sánchez‐Estévez, David Hardisson, David Sarrió, Jaime Prat, Juan C. Cigudosa, Xavier Matías‐Guiu, José Palacios	2003	98
20	Abnormal ezrin localization is associated with clinicopathological features in invasive breast carcinomas Breast Cancer Research and Treatment ·David Sarrió, Socorro Marıá Rodríguez-Pinilla, Ana Dotor, Francisco Calero Calero, David Hardisson, José Palacios	2006	96

About David Hardisson

David Hardisson is a scholar working on Oncology, Molecular Biology, Cancer Research, Pathology and Forensic Medicine and Reproductive Medicine, having authored 158 papers that have together received 7.0k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (26 papers), Endometrial and Cervical Cancer Treatments (17 papers), Cancer Genomics and Diagnostics (17 papers), Breast Cancer Treatment Studies (15 papers), Cancer Cells and Metastasis (13 papers), Cancer and Skin Lesions (11 papers), HER2/EGFR in Cancer Research (11 papers) and Breast Lesions and Carcinomas (11 papers). The work is most often cited by research in Cancer Research (1.9k citations), Oncology (2.6k citations), Obstetrics and Gynecology (530 citations), Reproductive Medicine (492 citations) and Molecular Biology (3.6k citations). David Hardisson has collaborated with scholars based in Spain, United States and United Kingdom. Frequent co-authors include David Sarrió, Gema Moreno‐Bueno, Socorro Marıá Rodríguez-Pinilla, José Palacios, Marta Mendiola, Amparo Cano, José Palacios, Francisco Calero Calero, C. Lomas and Maria Vinci. Their work appears in journals such as Modern Pathology, Journal of Clinical Oncology, Clinical & Translational Oncology, Histopathology and The Journal of Pathology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact